
ACLX
Healthcare · Biotechnology · $6.73B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2026
EPS trend, 90 days to now · +7.5% over 90 days · 30-day revisions 3 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 26, 2026 | Time not confirmed | -1.06 | -1.01 | +4.7% |
| Nov 5, 2025 | Time not confirmed | -0.96 | -0.99 | -3.1% |
| Aug 7, 2025 | Time not confirmed | -1.02 | -0.94 | +7.8% |
| May 8, 2025 | Time not confirmed | -0.76 | -1.13 | -48.7% |
| Feb 27, 2025 | Time not confirmed | -0.56 | -0.87 | -56.3% |
| Nov 8, 2024 | Time not confirmed | -0.34 | -0.48 | -41.2% |
| Aug 9, 2024 | Time not confirmed | -0.52 | -0.51 | +1.9% |
| May 9, 2024 | After the close | -0.51 | -0.14 | +72.5% |
| Feb 28, 2024 | After the close | -0.61 | 0.42 | +168.9% |
| Nov 13, 2023 | After the close | -0.54 | -0.81 | -50.0% |
| Aug 14, 2023 | After the close | -0.31 | -0.50 | -61.3% |
| May 8, 2023 | After the close | 1.82 | -0.58 | -131.9% |
| Mar 29, 2023 | After the close | -0.42 |
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in…
| -0.76 |
| -81.0% |
| Nov 14, 2022 | After the close | -0.89 | -2.12 | -138.2% |
| Aug 15, 2022 | After the close | -1.07 | -0.88 | +17.8% |
| May 12, 2022 | After the close | -0.95 | -1.56 | -64.2% |
| Mar 24, 2022 | After the close | -2.46 | -39.85 | -1519.9% |
| Dec 1, 2021 | Time not confirmed | -0.70 | -1.27 | -81.4% |